Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter
NCT ID: NCT04361500
Last Updated: 2020-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2020-04-15
2021-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19
NCT04547257
Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study
NCT04606498
Immunosupressive Treatment in COVID-19 Patients
NCT04382781
Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19
NCT04457349
Role of Microparticles in Covid-19 Infection
NCT04448743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 patients with Seraph 100 therapy
Seraph 100
Seraph 100 therapy during a COVID-19 infection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Seraph 100
Seraph 100 therapy during a COVID-19 infection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with the Seraph® 100 Microbind® Affinity Blood Filter
* Voluntary consent to participate in Registry
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick
UNKNOWN
Hannover Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Academic Teaching Hospital Brunswick
Braunschweig, Lower Saxony, Germany
Hannover Medical School
Hanover, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COSA-8998
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.